BERKELEY, CA--(Marketwired - Jul 2, 2013) - Dynavax Technologies Corporation (
Michael Ostrach, Chief Business Officer of Dynavax, will provide a corporate overview presentation. To access the slide presentation, live webcast, and subsequent archived recording, please visit Dynavax's website at http://investors.dynavax.com/newsevents.cfm.
Dynavax, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. Dynavax's lead product candidate is HEPLISAV™, a Phase 3 investigational adult hepatitis B vaccine. For more information visit www.dynavax.com.